Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis - PubMed (original) (raw)

Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis

W Paxton et al. J Virol. 1993 Dec.

Abstract

The product of the vpr open reading frame of human immunodeficiency virus type 1 (HIV-1) is a 15-kDa, arginine-rich protein that is present in virions in molar quantities equivalent to that of Gag. We report here the results of our investigations into the mechanism by which Vpr is incorporated into virions during assembly in infected cells. For these studies we used an expression vector encoding a Vpr molecule fused at its amino terminus to a nine-amino-acid peptide from influenza virus hemagglutinin. The tagged Vpr expression vector and a vpr mutant HIV-1 provirus were used to cotransfect COS cells, and the resulting virions were tested for the presence of the tagged protein on immunoblots probed with monoclonal antibody against the hemagglutinin peptide. The COS-produced virions were found to contain readily detectable amounts of tagged Vpr and smaller amounts of a putative tagged Vpr dimer. Infectivity of the particles was not altered by incorporation of tagged Vpr. Our results using this system in combination with mutant HIV-1 proviruses suggested that incorporation of Vpr into virions requires the carboxy-terminal Gag protein of HIV-1 (p6) but not gp160, Pol, or genomic viral RNA. In addition, analysis of mutated, tagged Vpr molecules suggested that amino acids near the carboxy terminus (amino acids 84 to 94) are required for incorporation of Vpr into HIV-1 virions. The single cysteine residue near the carboxy terminus was required for production of a stable protein. Arginine residues tested were not important for incorporation or stability of tagged Vpr. These results suggested a novel strategy for blocking HIV-1 replication.

PubMed Disclaimer

Cited by

Premature Activation of the HIV-1 Protease Is Influenced by Polymorphisms in the Hinge Region.
Tabler CO, Wegman SJ, Alhusaini N, Lee NF, Tilton JC. Tabler CO, et al. Viruses. 2024 May 26;16(6):849. doi: 10.3390/v16060849. Viruses. 2024. PMID: 38932142 Free PMC article.
Molecular Mechanisms of Neurodegenerative Diseases Induced by Human Retroviruses: A Review.
Irish BP, Khan ZK, Jain P, Nonnemacher MR, Pirrone V, Rahman S, Rajagopalan N, Suchitra JB, Mostoller K, Wigdahl B. Irish BP, et al. Am J Infect Dis. 2009 Jul 1;5(3):231-258. doi: 10.3844/ajidsp.2009.231.258. Am J Infect Dis. 2009. PMID: 20352020 Free PMC article.
The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate.
Mansky LM, Preveral S, Selig L, Benarous R, Benichou S. Mansky LM, et al. J Virol. 2000 Aug;74(15):7039-47. doi: 10.1128/jvi.74.15.7039-7047.2000. J Virol. 2000. PMID: 10888643 Free PMC article.
Characterization of human immunodeficiency virus type 1 Vif particle incorporation.
Camaur D, Trono D. Camaur D, et al. J Virol. 1996 Sep;70(9):6106-11. doi: 10.1128/JVI.70.9.6106-6111.1996. J Virol. 1996. PMID: 8709234 Free PMC article.
Human immunodeficiency virus type 1 and related primate lentiviruses engage clathrin through Gag-Pol or Gag.
Popov S, Strack B, Sanchez-Merino V, Popova E, Rosin H, Göttlinger HG. Popov S, et al. J Virol. 2011 Apr;85(8):3792-801. doi: 10.1128/JVI.02329-10. Epub 2011 Feb 2. J Virol. 2011. PMID: 21289110 Free PMC article.

References

1. J Virol. 1990 Jun;64(6):3097-9 - PubMed
1. J Virol. 1990 Jun;64(6):2743-50 - PubMed
1. J Virol. 1990 Oct;64(10):5230-4 - PubMed
1. J Virol. 1990 Nov;64(11):5688-93 - PubMed
1. Proc Natl Acad Sci U S A. 1990 Oct;87(20):8080-4 - PubMed

Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis - PubMed (original) (raw)